Evidence map›Paper›PMID 25339524›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2015

Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer.

Nai-Ming Cheng, Yu-Hua Dean Fang, Li-yu Lee, Joseph Tung-Chieh Chang, Din-Li Tsan, Shu-Hang Ng, Hung-Ming Wang, Chun-Ta Liao, Lan-Yan Yang, Ching-Han Hsu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Textural features of hypoxia PET predict survival in head and neck cancer during chemoradiotherapy.European journal of nuclear medicine and molecular imaging · 2020
    Trial
  4. Trial
  5. Article
  6. Article
  7. Texture analysis and metabolic parameters ofEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Computed tomography-based radiomics signature as a pretreatment predictor of progression-free survival in locally advanced hypopharyngeal carcinoma with a different response to induction chemotherapy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Article
  16. Review
  17. Review
  18. A review on advances inInsights into imaging · 2022
    Review
  19. Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Nai-Ming ChengDepartments of Nuclear Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taiyuan, Taiwan.
Yu-Hua Dean Fang
Li-yu Lee
Joseph Tung-Chieh Chang
Din-Li Tsan
Shu-Hang Ng
Hung-Ming Wang
Chun-Ta Liao
Lan-Yan Yang
Ching-Han Hsu
Tzu-Chen Yen
Chang Gung Memorial Hospital · TWChang Gung University · TWNational Tsing Hua University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe question as to whether the regional textural features extracted from PET images predict prognosis in oropharyngeal squamous cell carcinoma (OPSCC) remains open. In this study, we investigated the prognostic impact of regional heterogeneity in patients with T3/T4 OPSCC.

methodsWe retrospectively reviewed the records of 88 patients with T3 or T4 OPSCC who had completed primary therapy. Progression-free survival (PFS) and disease-specific survival (DSS) were the main outcome measures. In an exploratory analysis, a standardized uptake value of 2.5 (SUV 2.5) was taken as the cut-off value for the detection of tumour boundaries. A fixed threshold at 42 % of the maximum SUV (SUVmax 42 %) and an adaptive threshold method were then used for validation. Regional textural features were extracted from pretreatment (18)F-FDG PET/CT images using the grey-level run length encoding method and grey-level size zone matrix. The prognostic significance of PET textural features was examined using receiver operating characteristic (ROC) curves and Cox regression analysis.

resultsZone-size nonuniformity (ZSNU) was identified as an independent predictor of PFS and DSS. Its prognostic impact was confirmed using both the SUVmax 42 % and the adaptive threshold segmentation methods. Based on (1) total lesion glycolysis, (2) uniformity (a local scale texture parameter), and (3) ZSNU, we devised a prognostic stratification system that allowed the identification of four distinct risk groups. The model combining the three prognostic parameters showed a higher predictive value than each variable alone.

conclusionZSNU is an independent predictor of outcome in patients with advanced T-stage OPSCC, and may improve their prognostic stratification.

Indexed as

Fluorodeoxyglucose F18Positron-Emission TomographyRadiopharmaceuticalsAdultAgedAged, 80 and overCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedMultimodal ImagingOropharyngeal NeoplasmsPredictive Value of TestsSurvival AnalysisTomography, X-Ray ComputedFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID25339524
OpenAlexW2049691713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.